Evidence by population

Who was in peptide studies:
women, men, age and exclusions

There is no single answer: each study reports its own participants. Four published examples, and the difference between people who received a study peptide and people whose natural levels were measured.

Short answerCompound research · 5 min read · Updated 21 Nov 2026

There is no single answer: each peptide study enrols its own population. Four published examples: a BPC-157 pilot in 12 women aged 39 to 76; a BPC-157 pilot in one woman and one man; a GHK-Cu eyebrow study in 18 healthy adults aged 18 to 40; and a MOTS-c study that measured natural levels in 10 young men.

Key takeaways

  • Each example reports its own population; a total across four studies chosen as examples would describe the selection, not peptide research, so this page gives none.
  • Three of the studies gave a study peptide to their participants; the fourth measured naturally occurring MOTS-c in 10 men without giving them the peptide.
  • One sponsor-submitted record lists ages 18–45 and exclusions for pregnancy, breastfeeding, and some people subject to formal anti-doping testing. Those are listed criteria, not verified enrollment.
  • A study that includes women and men does not necessarily tell you whether their results differed.

01How many women and men were in these studies?

If you searched “peptides for women”, the question a study can answer is narrower: whom it enrolled, and whether it compared women and men. We chose four published human studies as examples; other studies of the same compounds exist and are not counted here. The table uses the groups the authors reported and says so where the source we could read gives no figure. It is not a census of peptide research or a ranking for women or men.

Human studyParticipantsWomenMenAgeStudy design and measures
BPC-157 · Lee, Walker and Ayadi (2024) [1]1212039–76 yearsT2, pilot without a control group; participant questionnaire. The study did not test material sold online.
BPC-157 · Lee and Burgess (2025) [2]211Woman: 68; man: 58T2, pilot without a control group; measures included blood tests and vital signs. Both people had received BPC-157 before. The study did not test material sold online.
GHK-Cu · Bo et al. (2026) [3, 4]18Not in the abstractNot in the abstract18–40 in the abstractT1, randomized within-person comparison with placebo; measures included eyebrow hair count and diameter. The study tested one specific formulation.
Natural MOTS-c levels · Reynolds et al. (2021) [5]10010Mean age 24.5 yearsT2, human exercise study; researchers measured naturally occurring MOTS-c in blood and muscle. They did not give the peptide to the men.

We give no total. These four studies were chosen as examples, asked different questions, and one gave no one a peptide, so a sum would describe the selection, not peptide research. A table of who took part also does not tell you whether women and men responded differently.

02What did the sources exclude by pregnancy, sport, and age?

Eligibility tells you who a study was designed to include, not who enrolled. The 2026 BPC-157 hamstring listing on ClinicalTrials.gov (NCT07437547) is a sponsor-submitted record. We use it here to describe the listed criteria, not as confirmation that anyone enrolled or received the peptide. It is not one of the four examples. [6, 7]

  • Pregnancy and breastfeeding. The hamstring listing excludes people who are pregnant or breastfeeding. It also lists a negative pregnancy test at baseline for participants who could become pregnant. These are study criteria, not evidence about pregnancy or breastfeeding. [6]
  • Formal anti-doping testing. The same listing allows organized recreational sport to meet its activity criterion. It separately excludes people “Currently subject to a formal anti-doping testing program” where “use of an investigational peptide could create a regulatory conflict”, unless the relevant authority explicitly approves. It does not list a blanket exclusion for everyone who plays sport. [6]
  • Age. The hamstring listing gives an eligible range of 18–45 years. The GHK-Cu eyebrow study’s abstract describes 18 healthy participants aged 18–40; we could not open the thesis that reports their actual ages. The older ages in the 2024 BPC-157 pilot describe that group, not an age rule for another study. [1, 3, 4, 6]

Sport rules are separate from study eligibility. The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 in section S0 and prohibits it at all times, in and out of competition. A line in a registry entry does not change that rule. See peptides and anti-doping for how to read the list. [8]

03How can you read a study’s participant count?

1
Find the group that actually enrolled

Look for a participant characteristics table or a results section. An enrollment target is not a head count. A field marked “All” under eligible sexes does not tell you how many women or men joined. [6, 9]

2
Check who received the intervention

In the Reynolds study, the men exercised and researchers measured a peptide already in their bodies. That is human evidence about a measured level, not a study of people receiving MOTS-c. [5]

3
Look for a direct comparison

A table showing women and men tells you who was represented. To answer whether they responded differently, look for a direct analysis that compares the groups, not just a result reported for everyone together. See our evidence grades for how study design shapes the conclusions.

04What we don’t know

These examples do not establish whether the same findings would apply during pregnancy or breastfeeding, to children, or to athletes subject to formal testing. Nor can you compare the women in one study with the men in another and call the difference a sex effect. The studies asked different questions, used different measures, and did not all administer a peptide. [1–6]

If your next question is what the human evidence can tell you about risk, read how to assess peptide safety. If your question is what a supplier’s paperwork actually verifies, see how to vet a peptide supplier. A participant table and a lab report answer different questions.

This is a plain-English summary of public studies and documents, checked on 21 November 2026. Not medical or legal advice.

RefSources

  1. 1. Lee E, Walker C, Ayadi B. [BPC-157 pilot with a participant questionnaire]. Alternative Therapies in Health and Medicine, 2024;30(10):12–17. PubMed record, PMID 39325560. pubmed.ncbi.nlm.nih.gov/39325560/
  2. 2. Lee E, Burgess K. [Two-person pilot safety study of BPC-157.] Alternative Therapies in Health and Medicine, 2025;31(5):20–24. PubMed record, PMID 40131143. pubmed.ncbi.nlm.nih.gov/40131143/
  3. 3. Bo SL, Nararatwanchai T, Supornpun N, Poomarapan K, Thaploka S. [Randomised, double-blind, split-face GHK-Cu eyebrow study in 18 healthy adults; poster presentation.] Procedia of Multidisciplinary Research, 2026;4(5):16. Official proceedings article page, hosted on Thai Journals Online by the series publishers, the Association of Legal & Political Studies and White Tiger Legal Business and Research Consultants. so09.tci-thaijo.org/index.php/PMR/article/view/9318
  4. 4. Bo SL. [Master’s thesis on the same GHK-Cu eyebrow study.] Mae Fah Luang University, 2025. Bibliographic record in the Thai Digital Collection. www.thailis.or.th/tdc/browse.php?browse_type=title&option=sh…
  5. 5. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c research with a human exercise component]. Nature Communications, 2021;12:470. Human methods and figure 1; PMCID PMC7817689. pmc.ncbi.nlm.nih.gov/articles/PMC7817689/
  6. 6. ClinicalTrials.gov. NCT07437547 [BPC-157 hamstring study listing]. Sponsor-submitted registry entry, 2026; participation criteria and estimated enrollment, not counted as human evidence. clinicaltrials.gov/study/NCT07437547
  7. 7. ClinicalTrials.gov. About ClinicalTrials.gov. Registry documentation; responsibility for submitted information. clinicaltrials.gov/about-site/about-ctg
  8. 8. World Anti-Doping Agency. 2026 Prohibited List, international standard, effective 1 January 2026, section S0. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  9. 9. ClinicalTrials.gov. How to Read Study Results. Registry documentation; participant flow and baseline characteristics. www.clinicaltrials.gov/study-basics/how-to-read-study-result…
  10. 10. U.S. Food and Drug Administration. BPC-157-related bulk drug substances. Pharmacy Compounding Advisory Committee briefing, July 2026; Appendix 1, human study summaries. www.fda.gov/media/193343/download

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Does the GHK-Cu eyebrow study say how many women took part?

Not in its published abstract, which describes 18 healthy participants aged 18 to 40. A split by sex, where a study gives one, describes who was included, not whether women and men responded differently.

Were the men in the Reynolds exercise study given MOTS-c?

No. The 2021 study measured naturally occurring MOTS-c in 10 men in an exercise experiment. It did not administer MOTS-c to the men.

Does excluding pregnancy tell us what happens during pregnancy?

No. A registered BPC-157 trial (NCT07437547) excludes pregnancy and breastfeeding. That criterion does not tell us what would happen in either group.

Is the eligible age range the same as the ages studied?

Not necessarily. An eligible age range says who could join; the ages of the people who did join come from a table of participant characteristics, which an abstract often leaves out.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page